M
Michael Leonardi
Publications - 10
Citations - 128
Michael Leonardi is an academic researcher. The author has contributed to research in topics: Rubella & Vaccination. The author has an hindex of 7, co-authored 10 publications receiving 117 citations.
Papers
More filters
Journal ArticleDOI
Time to Change Dosing of Inactivated Quadrivalent Influenza Vaccine in Young Children: Evidence From a Phase III, Randomized, Controlled Trial
Varsha K. Jain,Joseph B. Domachowske,Long Wang,Opokua Ofori-Anyinam,Miguel Angel Rodríguez-Weber,Michael Leonardi,Nicola P. Klein,Gary Schlichter,Robert Jeanfreau,Byron L. Haney,Laurence Chu,Jo Ann S. Harris,Kwabena O. Sarpong,Amanda C. Micucio,Jyoti Soni,Vijayalakshmi Chandrasekaran,Ping Li,Bruce L. Innis +17 more
TL;DR: Double-dose IIV4 may improve protection against influenza B in some young children and simplifies annual influenza vaccination by allowing the same vaccine dose to be used for all eligible children and adults.
Journal ArticleDOI
Immunogenicity, Safety, and Tolerability of a Hexavalent Vaccine in Infants
Gary S. Marshall,Gregory L Adams,Michael Leonardi,Maria Petrecz,Sheryl Flores,Angela L Ngai,Jin Xu,Guanghan Liu,Jon E. Stek,Ginamarie Foglia,Andrew W. Lee +10 more
TL;DR: DTaP5-IPV-Hib-HepB provides a new combination vaccine option aligned with the recommended US infant immunization schedule and the safety and immunogenicity are comparable with the analogous licensed component vaccines.
Journal ArticleDOI
Immunogenicity and safety of two tetravalent (measles, mumps, rubella, varicella) vaccines coadministered with hepatitis a and pneumococcal conjugate vaccines to children twelve to fourteen months of age.
Mark M. Blatter,Nicola P. Klein,Julie Shepard,Michael Leonardi,Steven Shapiro,Martin Schear,Maurice A. Mufson,Judith M. Martin,Meera Varman,Stanley E. Grogg,Arnold London,Pierre Cambron,Martine Douha,Ouzama Nicholson,Christopher da Costa,Bruce L. Innis +15 more
TL;DR: The vaccines showed acceptable reactogenicity/safety when coadministered with HAV and PCV7, and noninferiority of both GSK+4C and GSK-20C vaccines versus Merck-20 C was demonstrated for seroresponse rates to measles, mumps and rubella viruses.
Journal ArticleDOI
Safety and Immunogenicity of Human Serum Albumin-Free MMR Vaccine in US Children Aged 12-15 Months
Maurice A. Mufson,Clemente Diaz,Michael Leonardi,Christopher J. Harrison,Stanley E. Grogg,Antonio Carbayo,Simon Carlo-Torres,Robert Jeanfreau,Ana Quintero-Del-Rio,Gisele Bautista,Michael Povey,Christopher da Costa,Ouzama Nicholson,Bruce L. Innis +13 more
TL;DR: Immune responses were above threshold levels for projected protection against the 3 viruses from MMR-RIT lots with differing mumps virus titers, and MMR- RIT had an acceptable safety profile when co-administered with HAV, VAR, and PCV7.
Journal ArticleDOI
Immunogenicity and Safety of MMRV and PCV-7 Administered Concomitantly in Healthy Children
Michael Leonardi,Kenneth Bromberg,Roger Baxter,Julie L. Gardner,Stephanie O. Klopfer,Ouzama Nicholson,Michael Brockley,James Trammel,Vicky Leamy,Wendy R. Williams,Barbara J. Kuter,Florian Schödel +11 more
TL;DR: Similar immune responses between the groups support concomitant administration of the MMRV and PCV-7 to healthy children 12 to 15 months of age.